Latest Breaking News On - Tropical disease priority review voucher program - Page 2 : comparemela.com

Vanda Pharmaceuticals (VNDA) Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

Vanda Pharmaceuticals (VNDA) Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mihaelh polymeropoulosVanda pharmaceuticals incTropical disease priority review voucher programDrug administrationOrphan drug designationDrug designationPriority review voucherInvestigational new drugTropical diseases

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

/PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug.

District of columbiaUnited statesSan franciscoMihaelh polymeropoulosKevin moranUniversity of californiaVanda pharmaceuticals incDrug administrationPrnewswire vanda pharmaceuticals incTropical disease priority review voucher programExchange commissionHead of corporate affairsOrphan drug designationDrug designationPriority review voucherInvestigational new drug

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

/PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug.

District of columbiaUnited statesSan franciscoMihaelh polymeropoulosKevin moranUniversity of californiaVanda pharmaceuticals incDrug administrationPrnewswire vanda pharmaceuticals incTropical disease priority review voucher programExchange commissionHead of corporate affairsOrphan drug designationDrug designationPriority review voucherInvestigational new drug

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

WASHINGTON, Oct. 21, 2022 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration .

District of columbiaUnited statesSan franciscoMihaelh polymeropoulosKevin moranUniversity of californiaVanda pharmaceuticals incDrug administrationPrnewswire vanda pharmaceuticals incTropical disease priority review voucher programExchange commissionHead of corporate affairsOrphan drug designationDrug designationPriority review voucherInvestigational new drug